JP2010515752A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515752A5
JP2010515752A5 JP2009545674A JP2009545674A JP2010515752A5 JP 2010515752 A5 JP2010515752 A5 JP 2010515752A5 JP 2009545674 A JP2009545674 A JP 2009545674A JP 2009545674 A JP2009545674 A JP 2009545674A JP 2010515752 A5 JP2010515752 A5 JP 2010515752A5
Authority
JP
Japan
Prior art keywords
hcv
compound
inhibitor
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545674A
Other languages
English (en)
Japanese (ja)
Other versions
JP5306230B2 (ja
JP2010515752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050715 external-priority patent/WO2008089027A1/en
Publication of JP2010515752A publication Critical patent/JP2010515752A/ja
Publication of JP2010515752A5 publication Critical patent/JP2010515752A5/ja
Application granted granted Critical
Publication of JP5306230B2 publication Critical patent/JP5306230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545674A 2007-01-11 2008-01-10 C型肝炎の治療用化合物 Expired - Fee Related JP5306230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88445907P 2007-01-11 2007-01-11
US60/884,459 2007-01-11
PCT/US2008/050715 WO2008089027A1 (en) 2007-01-11 2008-01-10 Compounds for the treatment of hepatitis c

Publications (3)

Publication Number Publication Date
JP2010515752A JP2010515752A (ja) 2010-05-13
JP2010515752A5 true JP2010515752A5 (index.php) 2011-02-03
JP5306230B2 JP5306230B2 (ja) 2013-10-02

Family

ID=39431109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545674A Expired - Fee Related JP5306230B2 (ja) 2007-01-11 2008-01-10 C型肝炎の治療用化合物

Country Status (5)

Country Link
US (1) US7541351B2 (index.php)
EP (1) EP2099804B1 (index.php)
JP (1) JP5306230B2 (index.php)
CN (1) CN101631790B (index.php)
WO (1) WO2008089027A1 (index.php)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2009067108A1 (en) * 2007-11-20 2009-05-28 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
MX2010010235A (es) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.
MX2010010245A (es) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
AU2009228337A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
JP2014506255A (ja) 2010-12-30 2014-03-13 エナンタ ファーマシューティカルズ インコーポレイテッド フェナントリジン大環状c型肝炎セリンプロテアーゼ阻害剤
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1719773T3 (da) 2004-02-24 2009-06-29 Japan Tobacco Inc Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ATE469155T1 (de) * 2006-05-25 2010-06-15 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Similar Documents

Publication Publication Date Title
JP2010515752A5 (index.php)
JP2010521476A5 (index.php)
JP2010521481A5 (index.php)
JP2010521484A5 (index.php)
JP2010521482A5 (index.php)
JP2010521483A5 (index.php)
HRP20110194T1 (hr) Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b
JP2012512169A5 (index.php)
JP2012504132A5 (index.php)
JP2010510234A5 (index.php)
JP2012504632A5 (index.php)
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200612898A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
JP2008530096A5 (index.php)
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
JP2011523651A5 (index.php)
WO2004014313A3 (en) Combination pharmaceutical agents as inhibitors of hcv replication
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2005529069A5 (index.php)
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2011521965A5 (index.php)
JP2012528161A5 (index.php)
SI1615613T1 (sl) Kinoksalinilni makrociklični inhibitorji serinske proteaze hepatitisa C
JP2012511004A5 (index.php)